艾伯维收购获得的BCMA/CD3双抗ABBV-383在华申报临床，治疗 …
2024年1月9日 · ABBV-383 （ TNB-383B ）是由艾伯维和 TeneoOne 共同开发的一款针对 BCMA + CD3 的双特异性抗体，采用 2:1 设计，保持细胞杀伤能力的同时，还能降低细胞因子的释放。
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation …
2022年8月27日 · ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study …
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 ...
2023年11月2日 · ABBV-383 is an off-the-shelf, fully human B-cell maturation antigen (BMCA) X CD3 bispecific antibody with bivalent BCMA domain and low CD3 affinity that targets both …
AbbVie Advances Oncology Pipeline With Start of Multiple …
2024年6月5日 · ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA …
AbbVie Advances Oncology Pipeline With Start of Multiple …
2024年6月5日 · ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high...
A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 …
2022年11月15日 · ABBV-383 (formerly TNB-383B) is a BCMA × CD3 bispecific T-cell-redirecting antibody with 2 BCMA-binding domains and a low-affinity CD3-binding domain to potentially …
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA ...
2024年5月29日 · ABBV-383 is a distinctive next-generation BCMA x CD3 bispecific antibody composed of 2 high-affinity BCMA-binding domains, a low-affinity CD3-binding domain …
ABBV-383, a novel BCMA/CD3 bispecific antibody for the …
2022年11月23日 · ABBV-383 (previously known as TNB383B) is a monoclonal, B-cell maturation antigen (BCMA)-targeted, IgG4 bispecific antibody. 1 It features a low-activating CD3 receptor …
A Phase I First-in-Human Study of ABBV-383, a B-Cell ... - PubMed
2022年11月1日 · Purpose: ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I …
ABBV-383 (Abbvie) - HealthTree for Multiple Myeloma
2024年10月18日 · ABBV-383 is a unique bispecific antibody engineered to target both myeloma and T cells within the immune system. It is also unique as it is given intravenously (via IV) …